All Stories

  1. Quantum Mechanics-Based Ranking of Predicted Proteolysis Targeting Chimeras-Mediated Ternary Complexes
  2. AI ‐Based Protein Structure Predictions and Their Implications in Drug Discovery
  3. Alchemical Free Energy Workflows for the Computation of Protein-Ligand Binding Affinities
  4. Fighting COVID-19 with Artificial Intelligence
  5. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19
  6. Small-molecule modulators of serine protease inhibitor proteins (serpins)
  7. Structure–function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk
  8. New antitubercular isoniazid-based adamantane derivatives
  9. Inclusion of Quercetin in Gold Nanoparticles Decorated with Supramolecular Hosts Amplifies Its Tumor Targeting Properties
  10. Host–Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism
  11. Drug-Membrane Interactions in the Renin Angiotensin System
  12. Three Regioselectively Acylated Flavonoid Aglycone Derivatives in Equimolar Yield at One Blow
  13. Angiotensin II Type 1 Receptor Homology Models: A Comparison Between In Silico and the Crystal Structures
  14. Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability
  15. Molecular Dynamics Simulations on the Bioactive Molecule of hIAPP22–29 (NFGAILSS) and Rational Drug Design
  16. Rational Drug Design
  17. Tailoring Naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and In Vitro evaluation
  18. In vitro Controlled Release from Solid Pharmaceutical Formulations
  19. Exploring the interactions of irbesartan and irbesartan–2-hydroxypropyl-β-cyclodextrin complex with model membranes
  20. In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I).
  21. Open loop conformation of PhaZ7 Y105E mutant
  22. Closed loop conformation of PhaZ7 Y105E mutant
  23. Crystal structure analysis, covalent docking, and molecular dynamics calculations reveal a conformational switch in PhaZ7 PHB depolymerase
  24. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand
  25. The use of J-coupling as a sole criterion to assign the total absolute stereochemistry of new pyrrolidinone class synthetic analogs, derived from S-pyroglutamic acid
  26. Rational design and structure–activity relationship studies of quercetin–amino acid hybrids targeting the anti-apoptotic protein Bcl-xL
  27. The dynamic properties of angiotensin II type 1 receptor inverse agonists in solution and in the receptor site
  28. Mapping the interactions and bioactivity of quercetin⿿(2-hydroxypropyl)-β-cyclodextrin complex
  29. Antiplatelet effect of the main triterpenoids of an olive leaf extract
  30. A combined NMR and molecular dynamics simulation study to determine the conformational properties of rat/mouse 35-55 myelin oligodendrocyte glycoprotein epitope implicated in the induction of experimental autoimmune encephalomyelitis
  31. Deconvoluting the Dual Antiplatelet Activity of a Plant Extract
  32. PRESS: PRotEin S-Sulfenylation server
  33. Calixarenes in Lipase Biocatalysis and Cancer Therapy
  34. New hydrazones of 5-nitro-2-furaldehyde with adamantanealkanohydrazides: synthesis and in vitro trypanocidal activity
  35. Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor
  36. Rosemary tea consumption results to anxiolytic- and anti-depressant-like behavior of adult male mice and inhibits all cerebral area and liver cholinesterase activity; phytochemical investigation and in silico studies
  37. Rational Drug Design Paradigms: The Odyssey for Designing Better Drugs
  38. Branched-chain sugar nucleosides: stereocontrolled synthesis and bioevaluation of novel 3′-C-trifluoromethyl and 3′-C-methyl pyranonucleosides
  39. Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-β-cyclodextrin through Biophysical Techniques and Computational Methods
  40. Rational Drug Design and Synthesis of Molecules Targeting the Angiotensin II Type 1 and Type 2 Receptors
  41. A novel synthetic luteinizing hormone-releasing hormone (LHRH) analogue coupled with modified β-cyclodextrin: Insight into its intramolecular interactions
  42. The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan